Coalition for Clinical Trials Awareness Hosts Roundtable
Patient advocates, congressional staff and researchers to discuss how the federal government can increase clinical trials awareness
Patient advocates, congressional staff and researchers to discuss how the federal government can increase clinical trials awareness
Washington, DC – The Coalition for Clinical Trials Awareness (CCTA), of which the Alliance for Patient Access is the managing member, will host a Capitol Hill policy roundtable on Wednesday, May 3, “How Can the Federal Government Increase Clinical Trials Awareness?” The event, offering perspectives from patient advocates, an FDA official and a researcher, will discuss how the federal government can develop a strategy to increase clinical trials awareness and address the clinical trials under-enrollment problem. Congresswoman Diana DeGette (D-CO) will provide remarks highlighting the importance of clinical trials awareness and participation.
The event is part of the nationwide Clinical Trials Awareness Week, May 1-5, which is hosted by CCTA. The week’s activities also include a Twitter chat on May 2 and a social media campaign, “Cures begin with clinical trials awareness.”
Clinical trials are an essential step in getting medications approved by the FDA and onto pharmacy shelves for patients. Currently, there is a severe shortage of clinical trial participants, which slows the process of approving medications and moving them to market for patients. One study reported that 11% of clinical trials fail to enroll even one participant.
Consequently, many groundbreaking, life-saving medications remain stuck in the drug development pipeline. With increased participation in clinical trials, however, patients and care providers will have greater access to approved medications.
Clinical Trials Awareness Capitol Hill Policy Roundtable
Wednesday, May 3
11:30 a.m. – 1 p.m.
U.S. Capitol Visitors Center
Room SVC 214
Washington, DC
Panelists:
- Jonca Bull, MD - Assistant Commissioner, FDA Office of Minority Health
- Ellie Dehoney - Vice President, Policy and Advocacy, Research!America
- Renata Louwers - Patient Advocate, Clinical Trials Writer
- David Charles, MD - Chairman, Alliance for Patient Access & Medical Researcher
About The Coalition for Clinical Trials Awareness
The Coalition for Clinical Trials Awareness is a nonprofit group of health care providers, patient advocates, medical researchers and industry and government stakeholders working together to increase public awareness about the importance of clinical trials participation. http://cctawareness.org/
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
